Sunday, September 30, 2012

Why School? TED ebook author rethinks education when information is everywhere.



Why School? TED ebook author rethinks education when information is everywhere.
TED BLOG | SEPTEMBER 14, 2012
http://pulse.me/s/dj0mI


The Internet has delivered an explosion of learning opportunities for today's students, creating an abundance of information, ... Read more

--
Sent via Pulse/

Saturday, September 29, 2012

Surgical Resection of Cavernous Malformations of the Brainstem: Evolution of a Minimally Invasive Te

Publication year: 2012
Source:World Neurosurgery
Jeffrey C. Mai, Dinesh Ramanathan, Louis J. Kim, Laligam N. Sekhar
Objective The purpose of this study is to provide an institutional retrospective review of surgically treated brainstem cavernous malformations. Methods Between 2005 and 2010, 22 consecutive patients with brainstem cavernous malformations (15 females and 7 males) with a mean age of 43 underwent surgical treatment. Mean volume of the resected cavernous malformations was 0.65cm3. A minimally invasive resection technique was employed for these cases, in conjunction with skull base approaches. Results The mean follow-up period was 26.6 months (range 4-68 months). Of the 22 patients, 9% did not have clear evidence of hemorrhage at the time of presentation. Of the remainder, 22% had two or more MRI-documented instances of hemorrhage. Following resection and during follow-up, 54% of patients had an improvement in their mRS, while 14% were worse compared to their pre-operative presentation. 32% were unchanged. 9% of patients were found to have residual cavernoma post-surgery. Conclusion Our longitudinal experience has guided us to emphasize minimally invasive approaches during resection of the brainstem cavernous malformations, occasionally at the expense of achieving a complete resection, in order to improve patient outcomes.






Management of intracranial meningiomas in Enugu, Nigeria

Wilfred C Mezue, Samuel C Ohaegbulam, Chikandu A Ndubuisi, Mark C Chikani, David S Achebe

Surgical Neurology International 2012 3(1):110-110

Background: Meningiomas may range on presentation from incidentally identified small lesions to large symptomatic tumors in eloquent areas of the brain. Management options correspondingly vary and include careful observation, surgical excision, and palliative application of very limited therapeutic maneuvers in select cases. This paper discusses the options and difficulties in the management of meningiomas in a developing country. Methods: This study is a retrospective analysis of prospectively recorded data of patients managed for intracranial meningioma between January 2006 and September 2011 at Memfys Hospital for Neurosurgery, Enugu. Radiographic diagnosis of meningioma was based on computed tomography (CT) and or magnetic resonance imaging (MRI) criteria in all cases, but only patients who had surgery and a histological diagnosis were analyzed. Results: Seventy-four patients were radiographically diagnosed with intracranial meningioma over the period under review. Fifty-five patients were operated upon and 52 (70.3%) with histological diagnosis of meningioma were further analyzed. Histological diagnosis was complete in 42 (56.8%) patients and in 10 (13.5%) patients the subtype of meningioma was not determined. The male to female ratio was 1:1.08. The peak age range for females was in the 6th decade and for males in the 5th decade. The locations were olfactory groove (26.9%), convexity (21.2%), parasagittal/falx (19.2%), sphenoid ridge (15.4%), tuberculum sellae (7.7%), tentorial (3.8%), and posterior fossa (5.8%). The most common clinical presentation was headaches in 67.3% followed by seizures (40.4%) and visual impairment (38.5%). Histology was benign (World Health Organization [WHO] grade 1) in 39 patients. One patient harbored an atypical and two had anaplastic tumors. Gross total resection of the tumor was achieved in 41 patients. Surgical mortality was 3.9%. Conclusion: Effective management of meningioma depends largely on adequate and complete surgical resection and results in good outcomes. Adequate preoperative assessment, including visual assessment, and hormonal assessment in olfactory groove and sphenoid region meningiomas, is necessary.





Friday, September 28, 2012

Wound healing after radiation therapy: Review of the literature

Radiation therapy is an established modality in the treatment of head and neck cancer patients. Compromised wound healing in irradiated tissues is a common and challenging clinical problem. The pathophysiology and underlying cellular mechanisms including the complex interaction of cytokines and growth factors are still not understood completely. In this review, the current state of research regarding the pathomechanisms of compromised wound healing in irradiated tissues is presented. Current and possible future treatment strategies are critically reviewed.





Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer

Up to 20% of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens, automatic de-escalation of care based on age is standard practice outside of tertiary care centers. We performed a retrospective review of all PCNSL patients aged 80 years or older treated at Memorial Sloan-Kettering Cancer Center from 1993 to 2011. Demographic and clinical variables were evaluated as predictors of survival by multivariate analysis. Twenty-three of 24 patients were treated with chemotherapy (92% with high-dose MTX, typically in combination with vincristine and procarbazine). One patient received ocular radiation alone for disease limited to the eyes. Response to treatment was noted in 62.5% of patients; 9 (37.5%) had refractory disease. Median overall survival was 7.9 months (95% confidence interval [CI]: 5.8–53), and median progression-free survival was 6.5 months (95% CI: 4.4–29.5). Two-year survival rate was 33%; 3-year survival rate was 17%. Three patients lived more than 4 years postdiagnosis. Most patients tolerated therapy well, and despite low baseline creatinine clearance, no significant renal toxicity was noted. Response status and deep brain involvement were identified as the most important predictors of survival. Multidrug regimens containing high-dose MTX are feasible and efficacious among the oldest patients, particularly those who achieve a complete response by their fifth treatment cycle. Aggressive therapy should be offered to select patients irrespective of advanced age.






Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade

The Hirntumorstudien (HIT)-LGG-1996 protocol offered a comprehensive treatment strategy for pediatric patients with low-grade glioma (LGG), ie, observation, surgery, adjuvant radiotherapy, and chemotherapy to defer the start of irradiation in young children. In this current study, we sought to determine clinical factors for progression and survival. Between October 1, 1996 and March 31, 2004, 1031 patients were prospectively recruited into an observation arm (n = 668) and a nonsurgical arm stratifying 12 months of vincristine-carboplatin chemotherapy (n = 216) and conventional radiotherapy/brachytherapy (n = 147) in an age-dependent manner. Median patient age was 6.9 years; 28 patients had diencephalic syndrome, 44 had dissemination, and 108 had neurofibromatosis type 1(NF-1). Main tumor location was the supratentorial midline (40.4%), and the main histology was pilocytic astrocytoma (67.9%). Following a median observation of 9.3 years, 10-year overall survival (OS) was 0.94 and 10-year event-free survival (EFS) was 0.47. Ten-year progression-free survival was 0.62 following radiotherapy and 0.44 following chemotherapy. Sixty-one of 216 chemotherapy patients received radiotherapy 0.3–8.7 years after initial diagnosis. By multivariate analysis, diencephalic syndrome and incomplete resection were found to be unfavorable factors for OS and EFS, age ≥11 years for OS, and supratentorial midline location for EFS. Dissemination, age <1 year, and nonpilocytic histology were unfavorable factors for progression following radiotherapy (138 patients); and diencephalic syndrome, dissemination, and age ≥11 years were unfavorable factors following chemotherapy (210 patients). NF-1 patients and boys experienced prolonged tumor stabilization with chemotherapy. A nationwide multimodal treatment strategy is feasible for pediatric LGG. Extended follow-up yielded results comparable to single-institution series for the treatment groups. Three-quarters of surviving chemotherapy patients have not yet received radiation therapy. Infants with or without diencephalic syndrome and dissemination bear the highest risk for death and progression following diagnosis or treatment.






Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the express

Tumor cycling hypoxia is now a well-recognized phenomenon in animal and human solid tumors. However, how tumor cycling hypoxia impacts chemotherapy is unclear. In the present study, we explored the impact and the mechanism of cycling hypoxia on tumor microenvironment-mediated chemoresistance. Hoechst 33342 staining and hypoxia-inducible factor–1 (HIF-1) activation labeling together with immunofluorescence imaging and fluorescence-activated cell sorting were used to isolate hypoxic tumor subpopulations from human glioblastoma xenografts. ABCB1 expression, P-glycoprotein function, and chemosensitivity in tumor cells derived from human glioblastoma xenografts or in vitro cycling hypoxic stress-treated glioblastoma cells were determined using Western blot analysis, drug accumulation and efflux assays, and MTT assay, respectively. ABCB1 expression and P-glycoprotein function were upregulated under cycling hypoxia in glioblastoma cells concomitant with decreased responses to doxorubicin and BCNU. However, ABCB1 knockdown inhibited these effects. Moreover, immunofluorescence imaging and flow cytometric analysis for ABCB1, HIF-1 activation, and Hoechst 3342 in glioblastoma revealed highly localized ABCB1 expression predominantly in potentially cycling hypoxic areas with HIF-1 activation and blood perfusion in the solid tumor microenvironment. The cycling hypoxic tumor cells derived from glioblastoma xenografts exhibited higher ABCB1 expression, P-glycoprotein function, and chemoresistance, compared with chronic hypoxic and normoxic cells. Tumor-bearing mice that received YC-1, an HIF-1α inhibitor, exhibited suppressed tumor microenvironment-induced ABCB1 induction and enhanced survival rate in BCNU chemotherapy. Cycling hypoxia plays a vital role in tumor microenvironment-mediated chemoresistance through the HIF-1–dependent induction of ABCB1. HIF-1 blockade before and concurrent with chemotherapy could suppress cycling hypoxia-induced chemoresistance.






Thursday, September 27, 2012

Malignant Peripheral Nerve Sheath Tumor of the Abducens Nerve and a Review of the Literature

Publication year: 2012
Source:World Neurosurgery
Jason Voorhies, Eyas M. Hattab, Aaron A. Cohen-Gadol
Objective Malignant peripheral nerve sheath tumors are rare, and intracranial occurrences are even more rare. Treatment strategies have varied widely. The authors report the first case of a malignant peripheral nerve sheath tumor of the abducens nerve and provide a literature review that includes 61 cases of intracranial malignant peripheral nerve sheath tumors. Data were analyzed based on age, sex, treatment, survival, immunohistochemical staining, location, tumor grade, and neurofibromatosis association. These tumors more often affect males and the patients affected have a mean age of 39 years. Most patients underwent subtotal or gross total resection and radiation. Intracranial location varied, but most tumors occurred in the cerebellopontine angle. The literature demonstrates that intracranial malignant peripheral nerve sheath tumors are a heterogeneous group. Their association with neurofibromatosis (NF) is less clear than their extracranial counterparts. Prognosis is poor, but surgical resection and radiation can enhance chances for longer survival. Our aim was to elucidate information about these tumors. Clinical Presentation A 30-year-old woman presented with a 6-month history of headaches and diplopia. Results Neurologic examination revealed no focal deficit. Imaging revealed a heterogeneously enhancing retroclival mass without bony destruction. The tumor originated from the ipsilateral abducens nerve and extended into Dorello's canal; it adhered to the brainstem and cranial nerves. Pathology was consistent with low-grade malignant peripheral nerve sheath tumor. Conclusion At 3-month followup, the patient walked with a cane with no further deficits except mild ataxia which resolved within 6 months. MRI revealed a small residual tumor adherent to basilar artery. At 1-year followup and following ocular surgery to correct lateral rectus palsy, the patient was neurologically intact.






"As duas culturas"

Em uma conversa recente com um amigo matemático do IMPA, ele me contou sobre uma palestra feita por João Moreira Salles (cineasta) na Academia Brasileira de Ciências. Nessa palestra, Salles falou sobre a super valorização das artes e humanidades em detrimento das ciências "duras" (matemática, física) e da engenharia, e as consequências do processo para o desenvolvimento tecnológico, científico





Prognosis of tinnitus after acoustic neuroma surgery - Surgical management of postoperative tinnitus

Publication year: 2012
Source:World Neurosurgery
Michihiro Kohno, Masanobu Shinogami, Hidehiko Yoneyama, Osamu Nagata, Shigeo Sora, Hiroaki Sato
Object Tinnitus is a bothersome symptom for patients with acoustic neuroma. We studied the possibility of surgical control of postoperative tinnitus associated with acoustic neuroma. Methods Postoperative changes and prognosis of tinnitus were studied in 367 patients treated surgically via a lateral suboccipital retrosigmoid approach. Results Postoperative prognosis of tinnitus was: resolved in 20%, improved in 22%, unchanged in 35%, changed in 10%, and worsened in 14% of 290 patients who had preoperative tinnitus, and no tinnitus in 78% and appeared in 22% of 77 patients without preoperative tinnitus. Prognosis of postoperative tinnitus was influenced by age, tumor size, preoperative hearing acuity, types of preoperative hearing disturbance, and conditions of the cochlear nerve after tumor resection. Worse prognosis of postoperative tinnitus in the preoperative tinnitus group was found in younger patients, smaller tumor size, better preoperative hearing function, and normal or retrocochlear type of hearing disturbance. Regarding the conditions of the cochlear nerve after tumor resection, prognosis of tinnitus was significantly worse in the group of anatomically preserved cochlear nerve without useful hearing than in the group of cut cochlear nerve. Conclusions Deciding whether to cut the cochlear nerve during acoustic neuroma surgery by referring to a flowchart we proposed in cases where hearing preservation is not intended or judged less possible contributes to controlling postoperative tinnitus. However, regardless of whether the cochlear nerve was cut intraoperatively, tinnitus remained unchanged in 37% of patients, suggesting that their tinnitus originates in the brainstem or post-brainstem pathways before surgery, and it is considered difficult to control postoperative tinnitus in these cases.






Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotac

Abstract  
We investigate the variance in patterns of failure after Gamma Knife™ radiosurgery (GKRS) for patients with brain metastases based on the subtype of the primary breast cancer. Between 2000 and 2010, 154 breast cancer patients were treated with GKRS for brain metastases. Tumor subtypes were approximated based on hormone receptor (HR) and HER2 status of the primary cancer: Luminal A/B (HR+/HER2(−)); HER2 (HER2+/HR(−)); Luminal HER2 (HR+/HER2+), Basal (HR(−)/HER2(−)), and then based on HER2 status alone. The median follow-up period was 54 months. Kaplan–Meier method was used to estimate survival times. Multivariable analysis was performed using Cox regression models. Median number of lesions treated was two (range 1–15) with a median dose of 20 Gy (range 9–24 Gy). Median overall survival (OS) was 7, 9, 11 and 22 months for Basal, Luminal A/B, HER2, and Luminal HER2, respectively (p = 0.001), and was 17 and 8 months for HER2+ and HER(−) patients, respectively (p < 0.001). Breast cancer subtype did not predict time to local failure (p = 0.554), but did predict distant brain failure rate (76, 47, 47, 36 % at 1 year for Basal, Luminal A/B, HER2, and Luminal HER2 respectively, p < 0.001). An increased proportion of HER2+ patients experienced neurologic death (46 vs 31 %, p = 0.066). Multivariate analysis revealed that HER2+ patients (p = 0.007) independently predicted for improved survival. Women with basal subtype have high rates of distant brain failure and worsened survival. Our data suggest that differences in biologic behavior of brain metastasis occur across breast cancer subtypes.

  • Content Type Journal Article
  • Category Clinical Study
  • Pages 1-8
  • DOI 10.1007/s11060-012-0976-3
  • Authors
    • Tamara Z. Vern-Gross, Department of Radiation Oncology, Comprehensive Cancer Center, Baptist Medical Center, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • Julia A. Lawrence, Department of Medicine (Hematology & Oncology), Wake Forest University, Winston-Salem, NC, USA
    • L. Douglas Case, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, USA
    • Kevin P. McMullen, Department of Radiation Oncology, Comprehensive Cancer Center, Baptist Medical Center, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • J. Daniel Bourland, Department of Radiation Oncology, Comprehensive Cancer Center, Baptist Medical Center, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • Linda J. Metheny-Barlow, Department of Radiation Oncology, Comprehensive Cancer Center, Baptist Medical Center, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • Thomas L. Ellis, Department of Neurosurgery, Wake Forest University, Winston-Salem, NC, USA
    • Stephen B. Tatter, Department of Neurosurgery, Wake Forest University, Winston-Salem, NC, USA
    • Edward G. Shaw, Department of Radiation Oncology, Comprehensive Cancer Center, Baptist Medical Center, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • James J. Urbanic, Department of Radiation Oncology, Comprehensive Cancer Center, Baptist Medical Center, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • Michael D. Chan, Department of Radiation Oncology, Comprehensive Cancer Center, Baptist Medical Center, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA





Monday, September 24, 2012

III Congresso Brasileiro de RADIOCIRURGIA

Sobre o Evento

O III Congresso Brasileiro de Radiocirurgia será, sem dúvida, um evento multiprofissional. Além dos temas neurológicos, a integração com a oncologia será intensificada. 

A programação científica deste ano está mais ampla, abrangendo diversas especialidades com interesses comuns, tais como: Radioterapia, Neurologia, Neurocirurgia, Ortopedia, Cirurgia Torácia, Pneumologia, Cirurgia Oncológica, Cirurgia do Trato Gastrointestinal, Oncologia Clínica, Otorrinolaringologia e Endocrinologia.

Mensagem do Presidente

Caros colegas e colaboradores.

É com muita honra que Florianópolis sediará, nos dias 18 e 19 de outubro de 2012, o 3º Congresso Brasileiro de Radiocirurgia. Desde a fundação da nossa Sociedade, dois brilhantes eventos foram organizados com grande sucesso e competência, o primeiro em São Paulo e o segundo em Porto Alegre.

Com a evolução da especialidade, e com bases científicas cada vez mais sólidas, a Radiocirurgia ampliou de forma irreversível sua abrangência, fazendo com que repensemos o futuro e, porque não dizer, o presente.

Nossa parceria de sucesso com a neurocirurgia, já consolidada, precisa ser agora estendida para outras áreas de atuação. Como fazer a abordagem, como montar os times, são questões prementes. Não há dúvida que, sem envolvimento multiprofissional, essa expansão não será possível.

Por isso, optamos por ampliar o enfoque desta edição. Serão dois dias inteiros, esperamos intensos. O primeiro dia será focado nos temas relacionados às afecções benignas cerebrais. No segundo dia, de forma contundente, focaremos em SBRT de coluna, pulmão e trato digestivo. Outro tópico de extrema importância será o de oligometástases, cada vez mais presente na prática clínica.

Assim sendo, esperamos todos vocês em outubro, com uma programação diversificada e, de quebra, um cenário de fundo exuberante.

Abraços,

Arno Lotar Cordova Jr. 

Marcelo Neves Linhares


Comissões

Comissão Organizadora

Dr. Arno Lotar Cordova Jr.
Presidente
Dr. Marcelo Neves Linhares
Vice-Presidente
Dr. Ernani Lange de São Thiago
Presidente de Honra

Sociedade Brasileira de Radiocirurgia

Eduardo Weltman
Presidente
Leonardo Frighetto
Vice-Presidente

Comissão Científica

Dr. Arno Lotar Cordova Jr.
Dr. Carlos Genésio B. Lima Jr.
Dr. Eduardo Weltman
Dr. Evandro Cesar de Souza
Dr. Leonardo Frigheto
Dr. Marcelo Neves Linhares

Convidados

Internacionais

Dr. Alessandra Gorgulho (EUA)
Dr. Anand Mahadevan (EUA)
Dr. Antonio De Salles (EUA)
Dr. Ben J. Slotman (Holanda)
Dr. Júlio César Antic (Argentina) 
Dr. Reinhard Wurm (Alemanha)
Dr. Steven Chmura (EUA)

Nacionais

Dr. Andrei Koerbel (SC)
Dr. Carlos A. Buchpiguel (SP)
Dr. Concetta Esposito (SC)
Dr. Evandro de Oliveira (SP)
Dr. José Guilherme M. P. Caldas
Dr. Marcos Vinícius C. Maldaum (SP)
Dr. Nina Rosa Castro Musolino (SP)
Dr. Olavo Feher (SP)
Dr. Rafael Ferreira (SC)
Dr. Roberto K. Sakuraba (SP)
Dr. Robson Ferrigno (SP)
Dr. William G. J. Teixeira (SP)



Sunday, September 23, 2012

What Is the Optimal Treatment of Large Brain Metastases? An Argument for a Multidisciplinary Approac

Purpose: Single-modality treatment of large brain metastases (>2 cm) with whole-brain irradiation, stereotactic radiosurgery (SRS) alone, or surgery alone is not effective, with local failure (LF) rates of 50% to 90%. Our goal was to improve local control (LC) by using multimodality therapy of surgery and adjuvant SRS targeting the resection cavity.Patients and Methods: We retrospectively evaluated 97 patients with brain metastases >2 cm in diameter treated with surgery and cavity SRS. Local and distant brain failure (DF) rates were analyzed with competing risk analysis, with death as a competing risk. The overall survival rate was calculated by the Kaplain-Meier product-limit method.Results: The median imaging follow-up duration for all patients was 10 months (range, 1–80 months). The 12-month cumulative incidence rates of LF, with death as a competing risk, were 9.3% (95% confidence interval [CI], 4.5%–16.1%), and the median time to LF was 6 months (range, 3–17 months). The 12-month cumulative incidence rate of DF, with death as a competing risk, was 53% (95% CI, 43%–63%). The median survival time for all patients was 15.6 months. The median survival times for recursive partitioning analysis classes 1, 2, and 3 were 33.8, 13.7, and 9.0 months, respectively (p = 0.022). On multivariate analysis, Karnofsky Performance Status (≥80 vs. <80; hazard ratio 0.54; 95% CI 0.31–0.94; p = 0.029) and maximum preoperative tumor diameter (hazard ratio 1.41; 95% CI 1.08–1.85; p = 0.013) were associated with survival. Five patients (5%) required intervention for Common Terminology Criteria for Adverse Events v4.02 grade 2 and 3 toxicity.Conclusion: Surgery and adjuvant resection cavity SRS yields excellent LC of large brain metastases. Compared with other multimodality treatment options, this approach allows patients to avoid or delay whole-brain irradiation without compromising LC.





MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomi

Purpose: Recently, cells deficient in O6-methylguanine–DNA methyltransferase (MGMT) were found to show increased sensitivity to temozolomide (TMZ). We evaluated whether hypermethylation of MGMT was associated with survival in patients with glioblastoma multiforme (GBM).Methods and Materials: We retrospectively analyzed 93 patients with histologically confirmed GBM who received involved-field radiotherapy with TMZ from 2001 to 2008. The median age was 58 years (range, 24–78 years). Surgical resection was total in 39 patients (42%), subtotal in 30 patients (32%), and partial in 17 patients (18%); only a biopsy was performed in 7 patients (8%). Postoperative radiotherapy began within 3 weeks of surgery in 87% of the patients. Radiotherapy doses ranged from 50 to 74 Gy (median, 70 Gy). MGMT gene methylation was determined in 78 patients; MGMT was unmethylated in 43 patients (55%) and methylated in 35 patients (45%). The median follow-up period was 22 months (range, 3–88 months) for all patients.Results: The median overall survival (OS) was 22 months, and progression-free survival (PFS) was 11 months. MGMT gene methylation was an independently significant prognostic factor for both OS (p = 0.002) and PFS (p = 0.008) in multivariate analysis. The median OS was 29 months for the methylated group and 20 months for the unmethylated group. In 35 patients with methylated MGMT genes, the 2-year and 5-year OS rates were 54% and 31%, respectively. Six patients with combined prognostic factors of methylated MGMT genes, age ≤50 years, and total/subtotal resections are all alive 38 to 77 months after operation, whereas the median OS in 8 patients with unmethylated MGMT genes, age >50 years, and less than subtotal resection was 13.2 months.Conclusion: We confirmed that MGMT gene methylation is a potent prognostic factor in patients with GBM. Our results suggest that early postoperative radiotherapy and a high total/subtotal resection rate might further improve the outcome.





Radiosurgery for Para-IAC Meningiomas: The Effect of Radiation Dose to the Cochlea on Hearing Outcom

Purpose: This study was performed to assess the radiosurgical results of meningiomas extending into the internal acoustic canal (para-IAC meningiomas), with a particular focus on the effect of radiation dose to the cochlea on hearing outcome.Methods and Materials: A total of 50 patients who underwent radiosurgery for para-IAC meningiomas between 1998 and 2009, which were followed for 2 years, were enrolled. The mean age was 55.8 years (range, 15–75). The mean tumor volume was 6.1 cm3 (range, 1.0–19.0), the mean tumor length in the IAC was 6.9 mm (range, 1.3–13.3), and the mean prescribed marginal dose was 13.1 Gy (range, 10–15) at an isodose line of 50%. The mean follow-up duration was 46 months (range, 24–122).Results: Eight (16.0%) patients had nonserviceable hearing at the time of surgery. At the last follow-up, the tumor control rate was 94%; unchanged in 17 patients, decreased in 30 patients, and increased in 3 patients. Among 42 patients with serviceable hearing at the time of radiosurgery, it was preserved in 41 (97.6%) patients at the last follow-up. The maximal and mean radiation doses to the cochleae of these 41 patients were 5.8 Gy ± 0.3 (range, 3.1–11.5) and 4.3 Gy ± 0.2 (range, 2.2–7.5), respectively. The maximal dose to the cochlea of the patient who lost hearing after radiosurgery was 4.7 Gy.Conclusions: The radiation dose to the cochlea may have the minimal toxic effect on the hearing outcome in patients who undergo radiosurgery for para-IAC meningiomas.





A Multimodal Approach Including Craniospinal Irradiation Improves the Treatment Outcome of High-risk

Purpose: To evaluate whether a multimodal approach including craniospinal irradiation (CSI) improves treatment outcome in nongerminomatous germ cell tumor (NGGCT) patients.Methods and Materials: We reviewed the records of 32 patients with NGGCTs. Fourteen patients belonged to the intermediate prognosis group (immature teratoma, teratoma with malignant transformation, and mixed tumors mainly composed of germinoma or teratoma), and 18 patients belonged to the poor prognosis group (other highly malignant tumors). Patients with pure germinoma or mature teratoma were excluded from this study. Nineteen patients were treated with a combination of surgery, chemotherapy, and radiotherapy (RT); 9 patients received chemotherapy plus RT; 3 patients received surgery plus RT; and 1 patient received RT alone. Twenty-seven patients received CSI with a median of 36 Gy (range, 20–41 Gy) plus focal boost of 18–30.6 Gy, and 5 patients received whole-brain RT (WBRT) (20–36 Gy) or focal RT (50.4–54 Gy). The rate of total and subtotal resection was 71.9%. The median follow-up for surviving patients was 121 months.Results: Treatment failed in 7 patients. Three of the 5 patients who received focal RT or WBRT had local failure. Four cerebrospinal fluid (CSF) failures occurred after CSI. No failure occurred in the intermediate prognosis group. Ten-year recurrence-free survival (RFS) and overall survival (OS) for all patients were 77.6% and 74.6%, respectively. Ten-year RFS for the intermediate and poor prognosis groups were 100% and 61.1%, respectively (p = 0.012). OS for the two groups were 85.1% and 66.7%, respectively (p = 0.215). Tumor histology and CSI were significant prognostic factors for RFS, and CSI was significantly associated with OS.Conclusions: A multimodal approach was effective for treating NGGCTs. CSI should be considered for patients with poor prognostic histology.





Gamma Knife Radiosurgery for Symptomatic Brainstem Intra-axial Cavernous Malformations

Publication year: 2012
Source:World Neurosurgery
Seong-Hyun Park, Sung-Kyoo Hwang
Objective The purpose of this study was to evaluate the efficacy and safety of gamma knife radiosurgery (GKRS) for the treatment of symptomatic brainstem intraaxial cavernous malformations (CMs) associated with high surgical morbidity. Methods Twenty-one patients with symptomatic brainstem intra-axial CMs were treated by GKRS between 2005 and 2010. One patient was lost to follow up. The median age of the patients was 39.5 years (range 24−69 years). All patients had experienced 1 or more symptomatic hemorrhages before GKRS (range 1−3). The median marginal radiation dose was 13 Gy, and the median volume of the malformation was 0.56 mL. The median follow-up period after radiosurgery was 32 months (range 12−82 months, mean 38.9 months). Results Before GKRS, 31 hemorrhages (1.55 per patient) were observed. The annual hemorrhage rate before GKRS was 39.5%, excluding the first hemorrhage. After GKRS, 1 hemorrhage (0.05 per patient) was identified. It occurred 6 months after radiosurgery. The patient showed complete recovery to a premorbid status with steroid medication. The annual hemorrhage rate after GKRS was 8.2% for the first 2 years. After the expected latency period, no hemorrhages were identified. One patient (5%) exhibited permanent paresthesia, which was a new neurological symptom in absence of any hemorrhagic event, after the radiosurgery. Conclusions GKRS seems to be relatively effective and safe for reducing the rebleeding rate of brainstem intra-axial CMs that have high surgical risk. Carefulselection of a low margin dose and an optimal radiosurgical technique are helpful toachieve good outcomes.






Thursday, September 20, 2012

Brainstem diffuse glioma



Lucas Alverne F. Albuquerque

Craniopharyngioma



Lucas Alverne F. Albuquerque

Apps | Neurosurgery Blog


Apps

The Neurosurgery Blog group is developing a series of apps dedicated to medicine and more specifically neuroscience.

This is a space created to divulge our apps. You can found more information about than by clicking in the apps logos.

Let us know about your opinion, critics, suggestions or ideas in the "Contact us" space. With your help we may improve the apps you adquired and create new ones!

We hope you enjoy!

More apps are coming soon!




Poor science does not explain why papers are rejected

Sawka concludes that poor science, not conflicts of interest, explains why papers are rejected by leading journals, including the Journal of Applied Physiology and Medicine and Science in Sports and...





Age and Salvageability: Analysis of Outcome of Patients Older than 65 Years Undergoing Craniotomy fo

Publication year: 2012
Source:World Neurosurgery, Volume 78, Issues 3–4
Philipp Taussky, Eveline Teresa Hidalgo, Hans Landolt, Javier Fandino
Background We are in an aging population and many elderly people are prone to falling and suffering an acute traumatic subdural hematoma (aSDH). Yet, the operative treatment of patients older than 65 years of age for aSDH remains controversial, and very limited data exists with regard to expected outcome in this elderly patient group. Methods We retrospectively analyzed 37 consecutive patients (all >65 years) who underwent craniotomy for aSDH in our department between January 1, 2002 and December 31, 2007. Results Thirty-seven consecutive patients (54% women, 46% men) were treated for aSDH by means of craniotomy and duraplasty. Median age was 73 years (interquartile range, 10 years). Thirty patients (81%) had significant comorbidities and 43% of patients were treated by anticoagulation or thrombocyte aggregation inhibitors. Median initial Glasgow coma scale score was 8 (interquartile range, 7), and 51% had pupillary abnormalities. Perioperative morbidity occurred in 12 of 37 patients (32%), and 13 patients died in the postoperative period (35%). Overall outcome according to Glasgow outcome scale (GOS) was favorable (GOS, 4 and 5) in 15 of 37 patients (41%); severely disabled (GOS, 3) in 8 of 37 (22%), and unfavorable (GOS, 1 and 2) in 14 of 37 (38%). Conclusions Craniotomy for patients older than 65 years of age remains controversial, and our case series seems to support the notion that surgical treatment is associated with significant postoperative morbidity, mortality, and adverse outcome. However, selected patients benefit from an intervention, with a good outcome in 41% of patients.






Systematic reviews to evaluate causation: an overview of methods and application

Currently systematic reviews focus on diagnosis or effectiveness of treatment. It is the understanding of disease aetiology that underpins medical education, practice and research. Whether an association meets causal criteria is usually assessed qualitatively. However, this can also be examined through evidence synthesis and systematic reviews to evaluate disease causation and mechanisms are much needed. It is important in such a review to specify the questions to be addressed regarding causal criteria such as strength, consistency, temporality, specificity, biological gradient, plausibility and experimental evidence. The next step is to conduct a thorough literature search to identify the relevant studies and to assess them for their quality, particularly in relation to the risk of bias, ascertainment of exposures and ascertainment of outcomes. Data synthesis can then examine if the observed associations in collated studies are consistent, strong and temporal using techniques such as meta-analysis, testing for heterogeneity and meta-regression. Biological plausibility and coherence with existing theories can also be examined systematically through an assessment of the basic scientific literature. Experimental evidence might also be collated and synthesised to determine if removal of a causal agent alters the outcome. Through these steps a systematic review can help to establish whether an association is causal or not.






Tuesday, September 18, 2012

Cystic pituitary adenoma



Lucas Alverne F. Albuquerque

Brain metastasis



Lucas Alverne F. Albuquerque

Brain metastasis



Lucas Alverne F. Albuquerque

Anaplastic supratentorial cortical ependymoma presenting as a butterfly lesion

David W. K. Ng, Nicolas K. K. King, Aaron S. C. Foo, Yih-Yian Sitoh, Hwei Yee Lee, Wai Hoe Ng

Surgical Neurology International 2012 3(1):107-107

Background: Anaplastic cortical ependymomas are rare lesions with few cases reported in the literature. Case Description: We present a unique case of an anaplastic cortical ependymoma in a 51-year-old female presenting as a butterfly lesion with involvement of both frontal lobes. The patient underwent gross total resection of her tumor with further adjuvant treatment. We present the findings in our case and review the literature surrounding supratentorial ependymomas and their treatment outcomes. Conclusion: Rarely, cortical ependymoma can present as a butterfly lesion and should be considered in the differential diagnosis of such lesions in adults.





Current and Future Management of Brain Metastasis

Kim DG, Lundsford LD, eds. Current and Future Management of Brain Metastasis. Karger; 2012; 308 pages; $233.00.

The development of brain metastases has been the most feared complication of systemic cancer. In the past, once this complication occurred, all hope disappeared: the patient was considered to be terminal, and treatment efforts palliative. To improve the quality of life of cancer patients requires a thoughtful approach to the treatment of brain metastases and the development of new treatment options. For many years the standard therapy for metastatic brain tumors has been whole brain radiation therapy (WBRT), with surgical resection reserved for the few patients with limited systemic disease with single lesions in surgically accessible locations. The result of this limited approach has been disappointing and has the potential to cause significant morbidity. This has been the reason for the poor quality of life of the cancer patient with brain metastases and the lack of optimism. Although any systemic cancer has the potential to metastasize to the brain, tumors from lung and breast and malignant melanoma have the greatest propensity to do so and account for a large number of the 170,000 new cases of metastatic brain tumors in the United States yearly. The scope of this complication in oncology is tremendous.

An appreciation of this background is important to understand the impact of new developments in the treatment for metastatic brain tumors. Although improvements in neurosurgical techniques, delivery of WBRT, and the development of chemotherapy, immunotherapy, and, more recently, targeted therapy may all be listed as therapies improving the treatment of brain metastases, stereotactic radiosurgery (SRS), without question, has been the most important advancement to improve survival and quality of life for the cancer patient with brain metastases. The series Progress in Neurological Surgery published by Karger recognizes topics of interest in neurosurgery and invites editors of international reputation to personalize the topic by editing a volume of multi-authored chapters from authoritative specialists throughout the world. Since the series began in 1966, several editions have been dedicated to the various neurosurgical aspects of brain metastases. The most recent publication in this series, volume 25, entitled Current and Future Management of Brain Metastasis, addresses the challenges of brain tumor management with a focus on SRS. The volume editors, Dong Gyu Kim from Seoul and L. Dade Lunsford from Pittsburgh, have created a new addition to the series that provides a wealth of information from specialists around the globe regarding the role of SRS in the management of brain metastases, framed by a more general presentation of brain metastases management.

The publication is divided into five sections. The first section includes a general overview of brain metastases from a historical and epidemiological perspective, in the first two chapters, and then moves directly toward the emphasis of SRS with two separate chapters on pathophysiology and radiobiological principles of SRS. The second section is comprised of seven chapters that serve the purpose of providing a review of the various treatment modalities, including surgery, WBRT, chemotherapy, and SRS. This section appropriately begins with a chapter discussing the various diagnostic issues of neuroimaging of brain metastases. The placement and detail of this 18-page chapter from The University of California in San Francisco recognizes that the diagnostic issues are as important as the therapeutic issues in the treatment strategy of brain metastases. Choosing specialists from this institution to discuss this topic reflects the thoughtfulness of the editors in gathering the specialists with the most depth of thought and experience in each particular topic. Although this particular example is provided, each chapter is similar with the "best of the best," discussing one particular area of expertise with clarity. And though this section is meant to provide a general review, two of seven chapters focus on SRS. This section paves the way for the third section, which contains eleven chapters pertaining to the most important issues regarding SRS in the management of brain metastases. The third section entitled "Radiosurgery" is the centerpiece of the volume. The various chapters review, in explicit detail, the various SRS issues that are pertinent to patient management, including SRS dosing; treatment of specific tumor types such as lung, breast, renal cell, and melanoma; adverse effects of SRS; and combining SRS with surgical resection and WBRT. Although the chapters before and after this section provide depth to this volume, the chapters within this section provide the detail that will make this volume invaluable to specialists performing SRS, usually neurosurgeons and radiation oncologists. The overall selection of topics, quality of images, content of information, and clarity of presentation make this volume a useful reference for neuroradiologists, neuro-oncologists, medical oncologists, and neuropathologists. The fourth section builds on the clinical emphasis of this volume by presenting three chapters that address difficult clinical issues for SRS, including management of large tumors, multiple tumors, and recurrent tumors. The volume ends with a single chapter section reflecting on the future of management, with an emphasis on SRS.

This volume is a treasure for anyone involved with SRS. The organization, content, images, and references are consistent and of the best quality throughout the publication. This is not an easy accomplishment in a worldwide multi-authored publication, but reflects the thoughtfulness, expertise, and diligence of the editors and all of the contributors. The neuroradiologist plays an important role in the management of brain metastases. Although the neuroradiologist is not directly involved with performing SRS, the neuroradiologist provides diagnostic information regarding initial diagnosis and is crucial in  differentiating necrosis versus recurrence in the treated patient. Therefore, it is essential for the neuroradiologist to have a firm understanding of SRS, and this volume provides such a reference for all of the reasons discussed. There are other similar publications that have attempted to provide an overview of SRS, but this volume is outstanding. Full of pertinent information, this book is to-the-point and easy to follow. The references at the end of each chapter are carefully selected by each author and provide an excellent resource for the reader. The references represent the most comprehensive scholarly publications available regarding the topics covered in each chapter. The only criticism is that the title of this volume is perhaps somewhat misleading in that the physician may find the detailed emphasis on SRS overwhelming in contrast to the overview of other therapeutic modalities in the treatment armamentarium of metastatic brain tumors. Such a reader may be therefore critical of not finding the equivalent depth of coverage for all modalities, thereby missing  the rich wealth of information and experience regarding SRS and the major role this development plays to improve the survival and quality of life for patients inflicted with metastatic brain tumors.






The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children

Publication year: 2012
Source:Journal of Clinical Neuroscience
Nicolas R. Smoll, Katharine J. Drummond
Medulloblastomas (MB) and primitive neurectodermal tumours (PNET) are known to affect children more than adults. To estimate the magnitude of the differences between the incidence of adults and children, the incidence rates, ratios and time trends of MB and PNET in children and adults are measured using data from the Surveillance, Epidemiology and End-Results (SEER) database. Between 1973 and 2007 in the SEER 9 registries, 1372 people were diagnosed with a MB and 530 with a PNET. The overall incidence rate of MB and PNET is approximately 1.5 and 0.62 per million population in the USA. Children (1–9years of age) with MB had an incidence rate of 6.0, compared to 0.6 in adults, and therefore children are 10 times more likely to be affected by an MB than adults. Children are 4.6 times as likely to be afflicted by a PNET than adults. The difference in incidence rates based on sex existed only in children. Our study confirmed that the incidence rates of MB has not changed over time.






The impact of enrollment in clinical trials on survival of patients with glioblastoma

Publication year: 2012
Source:Journal of Clinical Neuroscience
Tal Shahar, Erez Nossek, David M. Steinberg, Uri Rozovski, Deborah T. Blumenthal, Felix Bokstein, Razi Sitt, Sigal Freedman, Benjamin W. Corn, Andrew A. Kanner, Zvi Ram
The impact of enrollment in a clinical study on the survival of patients with glioblastoma has not been established. We retrospectively analyzed 564 patients with newly diagnosed glioblastoma treated between 1995 and 2008. They were divided into those enrolled in a clinical trial and randomized to a treatment or control arm, and those not enrolled and who received best standard of care (BSC). The three groups were matched for age and Karnofsky performance scale (KPS) score at presentation, and included only patients who underwent at least one tumor resection. Survival analysis was performed and multivariate Cox proportional hazards model and recursive partitioning analysis (RPA) identified predictors of survival. Following the matching process, 261 patients remained to form the final cohort. Of the 124 patients enrolled in a study, 81 (31.0%) were randomized to the treatment and 43 (16.5%) to the control arms. The overall median survival for the BSC (n =137), control, and treatment groups was 11.57 months (95% confidence interval [CI], 10.41–12.73), 16.27 months (95% CI, 14.10–18.43) and 16.10 months (95% CI, 14.34–17.86), respectively (p =0.002). Participation in a clinical trial, regardless of the arm, was a significant predictor of survival, as were age and KPS at diagnosis. The RPA also demonstrated a favorable impact of participation in a clinical trial. Additional tumor resections and various treatment modalities were administered with significantly higher frequency among patients enrolled in clinical studies. Thus, enrollment in a clinical study carried a significant survival advantage for patients with glioblastoma, raising practical and ethical issues regarding the quality of care of patients who receive "standard" therapy.






Endoscopic resection of esthesioneuroblastoma

Publication year: 2012
Source:Journal of Clinical Neuroscience
Gary L. Gallia, Douglas D. Reh, Andrew P. Lane, Thomas S. Higgins, Wayne Koch, Masaru Ishii
Esthesioneuroblastoma, or olfactory neuroblastoma, is an uncommon malignant tumor arising in the upper nasal cavity. Surgical approaches to this and other sinonasal malignancies involving the anterior skull base have traditionally involved craniofacial resections. Over the past 10years to 15years, there have been advances in endoscopic approaches to skull base pathologies, including malignant tumors. In this study, we review our experience with purely endoscopic approaches to esthesioneuroblastomas. Between January 2005 and February 2012, 11 patients (seven men and four women, average age 53.3years) with esthesioneuroblastoma were treated endoscopically. Nine patients presented with newly diagnosed disease and two were treated for tumor recurrence. The modified Kadish staging was: A, two patients (18.2%); B, two patients (18.2%); C, five patients (45.5%); and D, two patients (18.2%). All patients had a complete resection with negative intraoperative margins. Three patients had 2-deoxy-2-(18F)fluoro-d-glucose avid neck nodes on their preoperative positron emission tomography–CT scan. These patients underwent neck dissections; two had positive neck nodes. Perioperative complications included an intraoperative hypertensive urgency and pneumocephalus in two different patients. Mean follow-up was over 28months and all patients were free of disease. This series adds to the growing experience of purely endoscopic surgical approaches in the treatment of skull base tumors including esthesioneuroblastoma. Longer follow-up on larger numbers of patients is required to clarify the utility of purely endoscopic approaches in the management of this malignant tumor.






Best Treatment Option For Childhood Cancer Offered By Whole-Genome Scan

A whole-genome scan to identify large-scale chromosomal damage can help doctors choose the best treatment option for children with neuroblastoma, one of the most common types of childhood cancer, finds an international collaboration jointly led by The Institute of Cancer Research, London...





Wednesday, September 12, 2012

Prolonged Survival and Serial Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy Changes in

Abstract: Krabbe disease may present during infancy, late infancy, or adulthood. Earlier-onset disease is associated with shorter survival times. We present a case of infantile onset Krabbe disease with prolonged survival, initial intracranial optic nerves and optic chiasm hypertrophy, and serial changes on cranial magnetic resonance imaging and magnetic resonance spectroscopy.